{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:48:49Z","timestamp":1784310529790,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background:<\/jats:title>\n Swallowed topical corticosteroids (STC) are an effective first-line therapy for patients with eosinophilic esophagitis (EoE), both for induction and maintenance of remission. All interventional trials with STC used twice-daily dosing regimens. However, in other inflammatory gastrointestinal disorders, corticosteroids are given once daily (OD) with equal outcomes and improved compliance.<\/jats:p>\n <\/jats:sec>\n \n Goals:<\/jats:title>\n To evaluate the effectiveness of topical budesonide maintenance treatment in a once-daily dosing schedule.<\/jats:p>\n <\/jats:sec>\n \n Study:<\/jats:title>\n Retrospective analysis of confirmed patients with EoE, treated with topical budesonide as maintenance therapy OD, with adequate follow-up available. Patients currently treated with budesonide were contacted to fill out online questionnaires regarding symptoms and health-related quality of life (HRQOL). The primary end point was histologic remission, defined as peak eosinophil count (PEC) <15 eosinophils per high power field (HPF) after >12 weeks of budesonide OD.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n We included 29 patients on STC OD (1\u00a0mg, N=28; 0.5\u00a0mg, N=1), either budesonide orodispersible tablet (BOT, Jorveza, Dr. Falk Pharma; N=12) or budesonide viscous solution (BVS; N=17). After a median follow-up of 767 days on OD dosing (range: 103 to 2396), 86% of patients were in histologic remission. Four patients had histologic disease activity, of which one was treated with BOT. Two patients experienced a slight increase in PEC after dose reduction of BVS to OD (to PEC of 25 and 35\/HPF, respectively). However, after switching the formulation to BOT OD they achieved histologic remission.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In this retrospective study, we demonstrated favorable results in the majority of patients treated with budesonide 1\u00a0mg OD as maintenance treatment for eosinophilic esophagitis.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/mcg.0000000000002139","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:20:30Z","timestamp":1738146030000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Effectiveness of Budesonide Once Daily as Maintenance Treatment of Eosinophilic Esophagitis"],"prefix":"10.1097","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-4734","authenticated-orcid":false,"given":"Karlien","family":"Raymenants","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vanuytsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"R1-20260105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"R2-20260105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13441","article-title":"Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies","volume":"43","author":"Arias","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-20260105","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0016-5085(95)90637-1","article-title":"Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula","volume":"109","author":"Kelly","year":"1995","journal-title":"Gastroenterology"},{"key":"R4-20260105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaci.2012.12.664","article-title":"Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease","volume":"131","author":"Lucendo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R5-20260105","first-page":"1419","article-title":"Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings","volume":"124","author":"Straumann","year":"1994","journal-title":"Schweiz Med Wochenschr"},{"key":"R6-20260105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01296781","article-title":"Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome","volume":"38","author":"Attwood","year":"1993","journal-title":"Dig Dis Sci"},{"key":"R7-20260105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O\u2019Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"R8-20260105","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/07853890.2022.2101689","article-title":"A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide","volume":"54","author":"Liu","year":"2022","journal-title":"Ann Med"},{"key":"R9-20260105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"R10-20260105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jgh.13281","article-title":"Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"31","author":"Murali","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R11-20260105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.dld.2022.05.004","article-title":"Treatment trends for eosinophilic esophagitis and the other eosinophilic gastrointestinal diseases: systematic review of clinical trials","volume":"55","author":"Visaggi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"R12-20260105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/1751-2980.12265","article-title":"Steroids therapy for eosinophilic esophagitis: systematic review and meta-analysis","volume":"16","author":"Tan","year":"2015","journal-title":"J Dig Dis"},{"key":"R13-20260105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"R14-20260105","doi-asserted-by":"crossref","first-page":"1756284820927282","DOI":"10.1177\/1756284820927282","article-title":"Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence","volume":"13","author":"Miehlke","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"R15-20260105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"key":"R16-20260105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"R17-20260105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"key":"R18-20260105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2011.01.017","article-title":"Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis","volume":"9","author":"Straumann","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20260105","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20260105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.crohns.2014.01.021","article-title":"Once versus three times daily dosing of oral budesonide for active Crohn\u2019s disease: a double-blind, double-dummy, randomised trial","volume":"8","author":"Dignass","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R21-20260105","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated International Consensus Diagnostic Criteria for eosinophilic esophagitis: proceedings of the AGREE Conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"R22-20260105","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2021.04.080","article-title":"Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS): an International Multidisciplinary Consensus","volume":"161","author":"Ma","year":"2021","journal-title":"Gastroenterology"},{"key":"R23-20260105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/a-1675-7860","article-title":"Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score","volume":"54","author":"Cotton","year":"2022","journal-title":"Endoscopy"},{"key":"R24-20260105","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","article-title":"Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis","volume":"147","author":"Schoepfer","year":"2014","journal-title":"Gastroenterology"},{"key":"R25-20260105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2036.2011.04791.x","article-title":"The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life","volume":"34","author":"Taft","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-20260105","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1053\/j.gastro.2020.02.039","article-title":"Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters","volume":"158","author":"Rank","year":"2020","journal-title":"Gastroenterology"},{"key":"R28-20260105","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/ajg.2017.202","article-title":"Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept","volume":"112","author":"Greuter","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R29-20260105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","article-title":"Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"R30-20260105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-022-00691-x","article-title":"Mechanisms and clinical management of eosinophilic oesophagitis: an overview","volume":"20","author":"Biedermann","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:00:51Z","timestamp":1767639651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002139","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"2024-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}